Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program
Biologics: Targets and Therapy · 2026-07 · Volume 20 · 1-11
DOI: 10.2147/btt.s581444 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biologics: Targets and Therapy, 2026-07. Verfasst von Rajesh Patel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- Patient Safety Pharmacovigilance, AstraZeneca, Gaithersburg, MD, USA.
- Biometrics, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- Research and Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- Late-stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
ORCID-Profile: Rajesh Patel, Gabriela Luporini Saraiva
Zitieren
APA
Patel, R., Brooks, D., Gorseth, E., Moate, R., Hofherr, A., Kell, C., Luporini Saraiva, G., Pandya, H., Jenkins, M., & Psallidas, I. (2026). Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program. Biologics: Targets and Therapy, Volume 20, 1-11. https://doi.org/10.2147/btt.s581444
Vancouver
Patel R, Brooks D, Gorseth E, Moate R, Hofherr A, Kell C, et al. Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program. Biologics: Targets and Therapy. 2026;Volume 20:1-11. doi:10.2147/btt.s581444
BibTeX
@article{Patel2026,
author = {Patel, Rajesh and Brooks, Dennis and Gorseth, Elise and Moate, Rachel and Hofherr, Alexis and Kell, Chris and Luporini Saraiva, Gabriela and Pandya, Hitesh and Jenkins, Martin and Psallidas, Ioannis},
title = {Safety Profile of Tozorakimab (an Anti-IL-33 Monoclonal Antibody): Data from the FRONTIER Phase 2 Program},
journal = {Biologics: Targets and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--11},
doi = {10.2147/btt.s581444}
}
EUVIMED